Similar articles for PMID: 23898092

Year	Number of Results
2005	6
2006	5
2007	3
2008	6
2009	6
2010	9
2011	10
2012	16
2013	33
2014	26
2015	30
2016	27
2017	29
2018	7
2019	5
2020	2
2021	4
2022	6
2023	5
2024	0

1

Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.

Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N. Imai H, et al. Anticancer Res. 2013 Aug;33(8):3279-84. Anticancer Res. 2013. PMID: 23898092

2

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.

Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ. Cho SH, et al. Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4. Cancer Chemother Pharmacol. 2012. PMID: 22760226

3

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR. Roengvoraphoj M, et al. Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Cancer Treat Rev. 2013. PMID: 23768755 Free article. Review.

4

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.

Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K. Yoshida T, et al. Lung Cancer. 2015 Dec;90(3):477-83. doi: 10.1016/j.lungcan.2015.09.025. Epub 2015 Oct 9. Lung Cancer. 2015. PMID: 26604031

5

Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.

Ikeda T, Nakamura Y, Yamaguchi H, Tomonaga N, Doi S, Nakatomi K, Iida T, Motoshima K, Mizoguchi K, Nagayasu T, Tsukamoto K, Kohno S. Ikeda T, et al. Clin Lung Cancer. 2012 Sep;13(5):369-74. doi: 10.1016/j.cllc.2012.01.008. Epub 2012 Mar 10. Clin Lung Cancer. 2012. PMID: 22410386

6

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ. Yi HG, et al. Lung Cancer. 2009 Jul;65(1):80-4. doi: 10.1016/j.lungcan.2008.10.016. Epub 2008 Dec 6. Lung Cancer. 2009. PMID: 19059670

7

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS. Park SJ, et al. Lung Cancer. 2012 Sep;77(3):556-60. doi: 10.1016/j.lungcan.2012.05.092. Epub 2012 Jun 5. Lung Cancer. 2012. PMID: 22677429 Clinical Trial.

8

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.

Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y. Kanda S, et al. Lung Cancer. 2015 Sep;89(3):287-93. doi: 10.1016/j.lungcan.2015.06.016. Epub 2015 Jul 2. Lung Cancer. 2015. PMID: 26169499

9

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.

Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ. Yeo CD, et al. Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14. Lung Cancer. 2015. PMID: 25617986

10

Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Wang J, Xia TY, Wang YJ, Li HQ, Li P, Wang JD, Chang DS, Liu LY, Di YP, Wang X, Wu WZ. Wang J, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e59-65. doi: 10.1016/j.ijrobp.2010.12.035. Epub 2011 Feb 23. Int J Radiat Oncol Biol Phys. 2011. PMID: 21345607

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

213 results

Results by year